The mammalian target of rapamycin modulates the immunoproteasome system in the heart

Journal of Molecular and Cellular Cardiology

Volumn 86, Issue , 2015, Pages 158-167

  Zhang, Hong Mei ^a   Fu, Jianliang ^b   Hamilton, Ryan ^c   Diaz, Vivian ^c   Zhang, Yiqiang ^c,d,e  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Heart; Immunoproteasome; Inflammation; MTOR; Proteasome; Rapamycin

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOPROTEASOME; MAMMALIAN TARGET OF RAPAMYCIN; PROTEASOME; RAPAMYCIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MTOR PROTEIN, MOUSE; OLIGOPEPTIDE; PR-957; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMEGALY; DRUG EFFECTS; GENETICS; HUMAN; PATHOLOGY; PHOSPHORYLATION;

MAMMALIA;

ANIMALS; CARDIOMEGALY; HUMANS; INTERFERON-GAMMA; MICE; NF-KAPPA B; OLIGOPEPTIDES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; SIROLIMUS; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION;

EID: 84938678109     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.07.027     Document Type: Article

References (83)

1. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
2. Zaytseva Y.Y., Valentino J.D., Gulhati P., Evers B.M. mTOR inhibitors in cancer therapy. Cancer Lett. 2012, 319:1-7.
3. Camici G.G., Steffel J., Amanovic I., Breitenstein A., Baldinger J., Keller S., et al. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur. Heart J. 2010, 31:236-242.
4. Shioi T., McMullen J.R., Tarnavski O., Converso K., Sherwood M.C., Manning W.J., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107:1664-1670.
5. Basler M., Dajee M., Moll C., Groettrup M., Kirk C.J. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J. Immunol. 2010, 185:634-641.
6. Stansfield W.E., Tang R.H., Moss N.C., Baldwin A.S., Willis M.S., Selzman C.H. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H645-H650.
7. Conn C.S., Qian S.B. mTOR signaling in protein homeostasis: less is more?. Cell Cycle 2011, 10.
8. Chang Y.Y., Neufeld T.P. An Atg1/Atg13 complex with multiple roles in TOR-mediated autophagy regulation. Mol. Biol. Cell 2009, 20:2004-2014.
9. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994, 79:13-21.
10. Jin H.K., Ahn S.H., Yoon J.W., Park J.W., Lee E.K., Yoo J.S., et al. Rapamycin down-regulates inducible nitric oxide synthase by inducing proteasomal degradation. Biol. Pharm. Bull. 2009, 32:988-992.
11. Buss S.J., Muenz S., Riffel J.H., Malekar P., Hagenmueller M., Weiss C.S., et al. Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J. Am. Coll. Cardiol. 2009, 54:2435-2446.
12. Wang X., Omura S., Szweda L.I., Yang Y., Berard J., Seminaro J., et al. Rapamycin inhibits proteasome activator expression and proteasome activity. Eur. J. Immunol. 1997, 27:2781-2786.
13. Wu W.K., Volta V., Cho C.H., Wu Y.C., Li H.T., Yu L., et al. Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells. Biochem. Biophys. Res. Commun. 2009, 386:598-601.
14. Ghosh P., Wu M., Zhang H., Sun H. mTORC1 signaling requires proteasomal function and the involvement of CUL4-DDB1 ubiquitin E3 ligase. Cell Cycle 2008, 7:373-381.
15. Zhang Y., Nicholatos J., Dreier J.R., Ricoult S.J., Widenmaier S.B., Hotamisligil G.S., et al. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 2014, 513:440-443.
16. Zolk O., Schenke C., Sarikas A. The ubiquitin-proteasome system: focus on the heart. Cardiovasc. Res. 2006, 70:410-421.
17. Chong Z.Z., Shang Y.C., Maiese K. Cardiovascular disease and mTOR signaling. Trends Cardiovasc. Med. 2011, 21:151-155.
18. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ. 2005, 12:1178-1190.
19. Portbury A.L., Ronnebaum S.M., Zungu M., Patterson C., Willis M.S. Back to your heart: ubiquitin proteasome system-regulated signal transduction. J. Mol. Cell. Cardiol. 2012, 52:526-537.
20. Willis M.S., Patterson C. Into the heart: the emerging role of the ubiquitin-proteasome system. J. Mol. Cell. Cardiol. 2006, 41:567-579.
21. Griffin T.A., Nandi D., Cruz M., Fehling H.J., Kaer L.V., Monaco J.J., et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J. Exp. Med. 1998, 187:97-104.
22. Aki M., Shimbara N., Takashina M., Akiyama K., Kagawa S., Tamura T., et al. Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J. Biochem. 1994, 115:257-269.
23. Puttaparthi K., Elliott J.L. Non-neuronal induction of immunoproteasome subunits in an ALS model: possible mediation by cytokines. Exp. Neurol. 2005, 196:441-451.
24. Foss G.S., Prydz H. Interferon regulatory factor 1 mediates the interferon-gamma induction of the human immunoproteasome subunit multicatalytic endopeptidase complex-like 1. J. Biol. Chem. 1999, 274:35196-35202.
25. Hallermalm K., Seki K., Wei C., Castelli C., Rivoltini L., Kiessling R., et al. Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 2001, 98:1108-1115.
26. Cai Z.P., Shen Z., Van Kaer L., Becker L.C. Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency. FASEB J. 2008, 22:4248-4257.
27. Yang Z., Gagarin D., St Laurent G., Hammell N., Toma I., Hu C.A., et al. Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1213-1219.
28. Pickering A.M., Koop A.L., Teoh C.Y., Ermak G., Grune T., Davies K.J. The immunoproteasome, the 20S proteasome and the PA28alphabeta proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem. J. 2010, 432:585-594.
29. Seifert U., Bialy L.P., Ebstein F., Bech-Otschir D., Voigt A., Schroter F., et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010, 142:613-624.
30. Szalay G., Meiners S., Voigt A., Lauber J., Spieth C., Speer N., et al. Ongoing coxsackievirus myocarditis is associated with increased formation and activity of myocardial immunoproteasomes. Am. J. Pathol. 2006, 168:1542-1552.
31. Cosper P.F., Harvey P.A., Leinwand L.A. Interferon-gamma causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditis. Am. J. Pathol. 2012, 181:2038-2046.
32. Jakel S., Kuckelkorn U., Szalay G., Plotz M., Textoris-Taube K., Opitz E., et al. Differential interferon responses enhance viral epitope generation by myocardial immunoproteasomes in murine enterovirus myocarditis. Am. J. Pathol. 2009, 175:510-518.
33. Anderson M., Moore D., Larson D. Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis. Perfusion 2008, 23:231-235.
34. Nagayama Y., Nakahara M., Shimamura M., Horie I., Arima K., Abiru N. Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice. Clin. Exp. Immunol. 2012, 168:268-273.
35. Whittaker P., Kloner R.A., Boughner D.R., Pickering J.G. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res. Cardiol. 1994, 89:397-410.
36. Lima C.F., Rattan S.I. Determination of proteasomal activities. Methods Mol. Biol. 2010, 648:183-192.
37. Schwartz A.L., Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 1999, 50:57-74.
38. Vinod V., Padmakrishnan C.J., Vijayan B., Gopala S. How can I halt thee? The puzzles involved in autophagic inhibition. Pharmacol. Res. 2014, 82:1-8.
39. Rivett A.J., Mason G.G., Murray R.Z., Reidlinger J. Regulation of proteasome structure and function. Mol. Biol. Rep. 1997, 24:99-102.
40. Rivett A.J., Bose S., Brooks P., Broadfoot K.I. Regulation of proteasome complexes by gamma-interferon and phosphorylation. Biochimie 2001, 83:363-366.
41. Ferrington D.A., Gregerson D.S. Immunoproteasomes: structure, function, and antigen presentation. Prog. Mol. Biol. Transl. Sci. 2012, 109:75-112.
42. Tanaka K. Role of proteasomes modified by interferon-gamma in antigen processing. J. Leukoc. Biol. 1994, 56:571-575.
43. Weichhart T., Costantino G., Poglitsch M., Rosner M., Zeyda M., Stuhlmeier K.M., et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008, 29:565-577.
44. Bergmann M.W., Loser P., Dietz R., von Harsdorf R. Effect of NF-kappa B Inhibition on TNF-alpha-induced apoptosis and downstream pathways in cardiomyocytes. J. Mol. Cell. Cardiol. 2001, 33:1223-1232.
45. Ortiz-Navarrete V., Seelig A., Gernold M., Frentzel S., Kloetzel P.M., Hammerling G.J. Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature 1991, 353:662-664.
46. Loukissa A., Cardozo C., Altschuller-Felberg C., Nelson J.E. Control of LMP7 expression in human endothelial cells by cytokines regulating cellular and humoral immunity. Cytokine 2000, 12:1326-1330.
47. Callahan M.K., Wohlfert E.A., Menoret A., Srivastava P.K. Heat shock up-regulates lmp2 and lmp7 and enhances presentation of immunoproteasome-dependent epitopes. J. Immunol. 2006, 177:8393-8399.
48. Meiners S., Dreger H., Fechner M., Bieler S., Rother W., Gunther C., et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 2008, 51:302-308.
49. Depre C., Wang Q., Yan L., Hedhli N., Peter P., Chen L., et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 2006, 114:1821-1828.
50. Drews O., Tsukamoto O., Liem D., Streicher J., Wang Y., Ping P. Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circ. Res. 2010, 107:1094-1101.
51. Basler M., Groettrup M. Immunoproteasome-specific inhibitors and their application. Methods Mol. Biol. 2012, 832:391-401.
52. Roos-Mattjus P., Sistonen L. The ubiquitin-proteasome pathway. Ann. Med. 2004, 36:285-295.
53. Powell S.R. The ubiquitin-proteasome system in cardiac physiology and pathology. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1-H19.
54. Joassard O.R., Amirouche A., Gallot Y.S., Desgeorges M.M., Castells J., Durieux A.C., et al. Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle. Int. J. Biochem. Cell Biol. 2013, 45:2444-2455.
55. Aronson L.I., Davenport E.L., Mirabella F., Morgan G.J., Davies F.E. Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application. Leukemia 2013, 27:2397-2403.
56. Hutter G., Zimmermann Y., Rieken M., Hartmann E., Rosenwald A., Hiddemann W., et al. Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL. Leukemia 2012, 26:2442-2444.
57. Shapira M., Kakiashvili E., Rosenberg T., Hershko D.D. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res. 2006, 8:R46.
58. Zu L., Bedja D., Fox-Talbot K., Gabrielson K.L., Van Kaer L., Becker L.C., et al. Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice. J. Mol. Cell. Cardiol. 2010, 49:5-15.
59. Voigt A., Rahnefeld A., Kloetzel P.M., Kruger E. Cytokine-induced oxidative stress in cardiac inflammation and heart failure-how the ubiquitin proteasome system targets this vicious cycle. Front. Physiol. 2013, 4:42.
60. Zhang Y., Bokov A., Gelfond J., Soto V., Ikeno Y., Hubbard G., et al. Rapamycin extends life and health in C57BL/6 mice. J. Gerontol. A: Biol. Med. Sci. 2013, 69:119-130.
61. Song X., Kusakari Y., Xiao C.Y., Kinsella S.D., Rosenberg M.A., Scherrer-Crosbie M., et al. mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am. J. Physiol. Cell Physiol. 2010, 299:C1256-C1266.
62. Takeda N., Manabe I. Cellular Interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. Int. J. Inflamm. 2011, 2011:535241.
63. Harston R.K., McKillop J.C., Moschella P.C., Van Laer A., Quinones L.S., Baicu C.F., et al. Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1696-H1706.
64. Lamming D.W., Ye L., Katajisto P., Goncalves M.D., Saitoh M., Stevens D.M., et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643.
65. Zeng Z., Sarbassov dos D., Samudio I.J., Yee K.W., Munsell M.F., Ellen Jackson C., et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007, 109:3509-3512.
66. Wang W., Yan J., Wang H., Shi M., Zhang M., Yang W., et al. Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. PLoS One 2014, 9:e83908.
67. Huang J., Manning B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 2009, 37:217-222.
68. Adkins J.R., Castresana M.R., Wang Z., Newman W.H. Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells. Am. Surg. 2004, 70:384-387. (discussion 7-8).
69. Nuhrenberg T.G., Voisard R., Fahlisch F., Rudelius M., Braun J., Gschwend J., et al. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J. 2005, 19:246-248.
70. Giordano A., Avellino R., Ferraro P., Romano S., Corcione N., Romano M.F. Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H2459-H2465.
71. Chen X., Zeng S., Zou J., Chen Y., Yue Z., Gao Y., et al. Rapamycin attenuated cardiac hypertrophy induced by isoproterenol and maintained energy homeostasis via inhibiting NF-kappaB activation. Mediat. Inflamm. 2014, 2014:868753.
72. Gao X.M., Wong G., Wang B., Kiriazis H., Moore X.L., Su Y.D., et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J. Hypertens. 2006, 24:1663-1670.
73. McMullen J.R., Sherwood M.C., Tarnavski O., Zhang L., Dorfman A.L., Shioi T., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
74. Smeets P.J., Teunissen B.E., Planavila A., de Vogel-van den Bosch H., Willemsen P.H., van der Vusse G.J., et al. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta. J. Biol. Chem. 2008, 283:29109-29118.
75. Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., Aukrust P. Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 2007, 9:236-241.
76. Ma F., Li Y., Jia L., Han Y., Cheng J., Li H., et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 2012, 7:e35144.
77. Lindner D., Zietsch C., Tank J., Sossalla S., Fluschnik N., Hinrichs S., et al. Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res. Cardiol. 2014, 109:428.
78. Balakumar P., Singh A.P., Ganti S.S., Krishan P., Ramasamy S., Singh M. Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy?. Basic Clin. Pharmacol. Toxicol. 2008, 102:5-9.
79. Kalogeropoulos A.P., Georgiopoulou V.V., Butler J. From risk factors to structural heart disease: the role of inflammation. Heart Fail. Clin. 2012, 8:113-123.
80. Deng L., Zhou J.F., Sellers R.S., Li J.F., Nguyen A.V., Wang Y., et al. A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am. J. Pathol. 2010, 176:952-967.
81. Zhao L., Ding T., Cyrus T., Cheng Y., Tian H., Ma M., et al. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. Br. J. Pharmacol. 2009, 156:774-785.
82. Chen W.Q., Zhong L., Zhang L., Ji X.P., Zhang M., Zhao Y.X., et al. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br. J. Pharmacol. 2009, 156:941-951.
83. Muchamuel T., Basler M., Aujay M.A., Suzuki E., Kalim K.W., Lauer C., et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 2009, 15:781-787.